Targeting epigenetic modifications as an emerging immunotherapeutic strategy for cancers

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Epigenetics involves modifications like DNA methylation and histone changes that regulate gene expression without altering DNA sequence.
• These epigenetic alterations are crucial in various cancers, including colorectal, breast, lung, glioblastoma, and hematologic malignancies.
• Epigenetic changes impact tumor initiation, progression, immune evasion, and the tumor-immune microenvironment.

Purpose of the Study:

• To review the complex interplay between epigenetic modifications and cancer immunity.
• To highlight how epigenetic mechanisms contribute to immune escape and resistance to therapies.
• To discuss the potential of epigenetic therapies and combinatorial strategies in cancer immunotherapy.

Main Methods:

• Literature review focusing on epigenetic mechanisms in cancer.
• Analysis of the role of DNA methylation, histone modifications, non-coding RNAs, and chromatin remodeling in cancer immunity.
• Examination of epigenetic drugs (DNMT, HDAC, BET inhibitors) and their combination with immune checkpoint inhibitors.

Main Results:

• Epigenetic alterations modulate antigen presentation, immune cell infiltration, and cytokine signaling, facilitating immune escape.
• Epigenetic therapies show promise in reprogramming immune responses and restoring anti-tumor immunity.
• Combinations of epigenetic modulators with immune checkpoint inhibitors may enhance treatment efficacy.

Conclusions:

• Epigenetic regulation is a critical factor in cancer immunity and a promising target for novel immunotherapies.
• Personalized epigenetic interventions and biomarker-driven approaches are essential for improving cancer immunotherapy outcomes.
• Targeting epigenetic modifications represents a key frontier in next-generation cancer treatment.